Generic Zomig and Vfend Launched by Ajanta Pharma

Article

Ajanta Pharma Limited has been given final approval from the FDA to launch zolmitriptan tablets, 2.5 mg and 5 mg, and voriconazole tablets, 50 mg and 200 mg.

Ajanta Pharma Limited has been given final approval from the FDA to launch zolmitriptan tablets, 2.5 mg and 5 mg, and voriconazole tablets, 50 mg and 200 mg.

The zolmitriptan tablets may be used for the acute treatment of migraines, and it is the bioequivalent generic version of Zomig, which is marketed by Impax Pharmaceuticals.

The most common adverse effects associated with zolmitriptan include nausea, pain, tingling sensation, and unusual taste. However, some individuals may also have an increased risk of heart attacks, high blood pressure, and stroke.

Two days after the approval of the zolmitriptan tablets, Ajanta announced that it had also received FDA approval for its voriconazole tablets, which are a generic version of Pfizer’s Vfend. Patients can use Ajanta’s generic version to treat serious invasive fungal infections.

Visual disturbances, fever, nausea, rash, vomiting, chills, headache, tachycardia, and hallucinations are some of the potential adverse effects associated with voriconazole.

To date, the FDA has granted 9 abbreviated new drug application final approvals and 2 tentative approvals to Ajanta Pharma Limited.

Recent Videos
Image credit:  Gorodenkoff | stock.adobe.com
Sun Screen, Photosensitivity, Pharmacy | Image Credit: sosiukin - stock.adobe.com
Catalyst Trial, Diabetes, Hypertension | Image Credit: grinny - stock.adobe.com
Various healthy foods -- Image credit: New Africa | stock.adobe.com
LGBTQIA+ pride -- Image credit: lazyllama | stock.adobe.com
Modern pharmacy building facade with large window showcasing the interior, as seen from the street view, promoting a welcoming atmosphere for customers. Frontal view. Generative AI - Image credit: Karrrtinki | stock.adobe.com
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com